---
schema_version: "secwatch.filing_event.v1"
accession: "0001564590-22-008030"
form_type: "8-K"
ticker: "SNDX"
cik: "0001395937"
company_name: "Syndax Pharmaceuticals Inc"
filed_at: "2022-03-01T23:59:59+00:00"
generated_at: "2026-06-27T02:53:31.478514+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Syndax reports Q4 net profit of $96.2M from Incyte deal; names new CMO

## Summary
- Net profit $96.2M ($1.81/sh) vs loss $20.4M prior Q; revenue $126.6M from Incyte collaboration.
- Cash $439.9M at Dec 31; FY2022 R&D guidance $130-140M, total opex $160-170M.
- Kate Madigan appointed CMO effective March 1, succeeding Michael Meyers who retires.
- Pivotal trials for SNDX-5613 and axatilimab enrollment on track; topline data expected 1H2023, potential NDA/BLA filing 2023.
- Three new trials of SNDX-5613 expected to initiate 1H2022.

## SEC filing metadata
- accession: 0001564590-22-008030
- form_type: 8-K
- ticker: SNDX
- cik: 0001395937
- company_name: Syndax Pharmaceuticals Inc
- filed_at: 2022-03-01T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 5.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1395937/000156459022008030/0001564590-22-008030-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1395937/000156459022008030/sndx-8k_20220301.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001564590-22-008030
- JSON: https://secwatch.observer/filing/0001564590-22-008030.json
- Plain text: https://secwatch.observer/filing/0001564590-22-008030.txt

## Key facts
- Executive change
  Kate Madigan was appointed as Chief Medical Officer at Syndax Pharmaceuticals Inc.
  - Action: appointed
  - Role: Chief Medical Officer
  source text: Kate Madigan, M.D. will join the Company as Chief Medical Officer, effective March 1, 2022.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1395937/000156459022008030/0001564590-22-008030-index.htm
- Executive change
  Michael L. Meyers departed as Chief Medical Officer at Syndax Pharmaceuticals Inc.
  - Action: retired and resigned
  - Role: Chief Medical Officer
  source text: Michael L. Meyers, M.D., Ph.D., Chief Medical Officer of the Company, notified the Company of his intention to retire and resign from his position as Chief Medical Officer.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1395937/000156459022008030/0001564590-22-008030-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.